• +1-646-491-9876
    • +91-20-67278686

    Search

    Receptor Tyrosine Protein Kinase ERBB 3-Pipeline Review H2 2017

    Receptor Tyrosine Protein Kinase ERBB 3-Pipeline Review H2 2017

    • Report Code ID: RW0001881479
    • Category Life Sciences
    • No. of Pages 101
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)-Pipeline Review H2 2017

    Summary

    According to the recently published report 'Receptor Tyrosine Protein Kinase ERBB 3-Pipeline Review H2 2017'; Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) pipeline Target constitutes close to 23 molecules. Out of which approximately 21 molecules are developed by companies and remaining by the universities/institutes.

    Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)-Receptor tyrosine-protein kinase erbB-3 or HER3 is a membrane bound protein encoded by the ERBB3 gene. It belongs to tyrosine-protein kinase family. It plays an essential role as cell surface receptor for neuregulins. It binds to neuregulin-1 (NRG1) and is activated by it. It also activated by CSPG5.

    The report 'Receptor Tyrosine Protein Kinase ERBB 3-Pipeline Review H2 2017' outlays comprehensive information on the Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics complete with analysis by indications stage of development mechanism of action (MoA) route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

    It also reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently The molecules developed by companies in Phase II Phase I IND/CTA Filed Preclinical and Discovery stages are 7 5 2 6 and 1 respectively. Similarly the universities portfolio in Preclinical stages comprises 2 molecules respectively. Report covers products from therapy areas Oncology which include indications Non-Small Cell Lung Cancer Breast Cancer Gastric Cancer Colorectal Cancer Head And Neck Cancer Squamous Cell Carcinoma Solid Tumor Melanoma Metastatic Breast Cancer Lung Cancer Pancreatic Cancer Bladder Cancer Cervical Cancer Esophageal Cancer Hepatocellular Carcinoma Lung Adenocarcinoma Metastatic Colorectal Cancer Ovarian Cancer Recurrent Head And Neck Cancer Squamous Cell Carcinoma Squamous Cell Carcinoma Adenocarcinoma Of The Gastroesophageal Junction Colorectal Tumor Endometrial Cancer Epithelial Tumor Ewing Sarcoma Head And Neck Cancer Hormone Refractory (Castration Resistant Androgen-Independent) Prostate Cancer Hypopharyngeal Cancer Laryngeal Cancer Malignant Mesothelioma Metastatic Adenocarcinoma of The Pancreas Metastatic Hepatocellular Carcinoma (HCC) Nasopharyngeal Cancer Neuroendocrine Tumors Oral Cavity (Mouth) Cancer Oropharyngeal Cancer Osteosarcoma Pancreatic Tumor Peritoneal Tumor Skin Cancer Small-Cell Lung Cancer Squamous Non-Small Cell Lung Cancer and Thyroid Cancer.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
    - The report reviews Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes product description descriptive MoA R&D brief licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA) route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information analysis and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)-Overview
    Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)-Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)-Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)-Companies Involved in Therapeutics Development
    AstraZeneca Plc
    AVEO Pharmaceuticals Inc
    Celldex Therapeutics Inc
    Daiichi Sankyo Company Ltd
    Etubics Corp
    F. Hoffmann-La Roche Ltd
    GlaxoSmithKline Plc
    Hanmi Pharmaceuticals Co Ltd
    Hummingbird Bioscience Pte Ltd
    ImmunoGen Inc
    MediaPharma Srl
    Merrimack Pharmaceuticals Inc
    Merus NV
    Novartis AG
    Shanghai Fosun Pharmaceutical (Group) Co Ltd
    Sorrento Therapeutics Inc
    Symphogen A/S
    Takis Srl
    XuanZhu Pharma Co Ltd
    Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)-Drug Profiles
    AV-203-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BA-0702-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CDX-3379-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    elgemtumab-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ETBX-031-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FCN-411-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2849330-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HMBD-001-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    huHER3-8-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    istiratumab-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lumretuzumab-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MCLA-125-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Antagonize HER-3 for Breast and Pancrestic Cancers-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MPEV-201959-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    patritumab-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pirotinib-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    poziotinib-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sapitinib-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    seribantumab-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    sirotinib-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit EGFR HER2 and HER3 for Oncology-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Sym-013-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TK-003-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)-Dormant Products
    Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)-Discontinued Products
    Receptor Tyrosine Protein Kinase ERBB 3 (Proto Oncogene Like Protein c ErbB 3 or Tyrosine Kinase Type Cell Surface Receptor HER3 or HER3 or ERBB3 or EC 2.7.10.1)-Product Development Milestones
    Featured News & Press Releases
    Jun 19 2017 Merrimack Announces Completion of Enrollment in Phase 2 CARRIE Study of MM-141; Data Expected in First Half of 2018
    Apr 03 2017 AVEO Announces Milestone Payment from CANbridge for AV-203
    Apr 03 2017 Hummingbird Bioscience presents update on HMBD-001 at AACR in Washington DC
    Mar 30 2017 Spectrum Pharmaceuticals Announces Initiation of a Phase 2 Trial of Poziotinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations
    Mar 27 2017 Merrimack to Present Data on Istiratumab (MM-141) at the 2017 American Association for Cancer Research Annual Meeting
    Dec 08 2016 Spectrum Pharmaceuticals Highlights Promising Preclinical Data Evaluating Poziotinib in Lung Cancer at the 17th IASLC World Conference on Lung Cancer
    Dec 05 2016 Spectrum Pharmaceuticals Presents Abstract on Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio Texas December 6-10 2016
    Nov 17 2016 Spectrum Pharmaceuticals Announces Poziotinib Data Presentation at the 17th IASLC World Conference on Lung Cancer in Vienna Austria December 4-7 2016
    Oct 25 2016 Anti-HER3 Monoclonal Antibody Patritumab Selected for I-SPY 2 TRIAL in Breast Cancer
    Sep 28 2016 Merrimack to Present a Poster on Seribantumab (MM-121) at the European Society for Medical Oncology 2016 Congress
    Aug 26 2016 CFDA Granted Approval of Phase I-III Clinical Trials for Sirotinib (XZP-5491)
    Aug 11 2016 CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody CAN-017 for Esophageal Squamous Cell Cancer
    Jul 06 2016 FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
    Jun 06 2016 Kolltan Pharmaceuticals Presents Clinical Data for KTN3379 in an Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
    May 31 2016 Daiichi Sankyo Provides Update on HER3-Lung Study of Patritumab in Non-Small Cell Lung Cancer
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Therapy Areas H2 2017
    Number of Products under Development by Indications H2 2017
    Number of Products under Development by Indications H2 2017 (Contd..1) H2 2017
    Number of Products under Development by Indications H2 2017 (Contd..2) H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017 (Contd..1) H2 2017
    Products under Development by Companies H2 2017 (Contd..2) H2 2017
    Products under Development by Companies H2 2017 (Contd..3) H2 2017
    Products under Development by Companies H2 2017 (Contd..4) H2 2017
    Number of Products under Investigation by Universities/Institutes H2 2017
    Products under Investigation by Universities/Institutes H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Pipeline by AstraZeneca Plc H2 2017
    Pipeline by AVEO Pharmaceuticals Inc H2 2017
    Pipeline by Celldex Therapeutics Inc H2 2017
    Pipeline by Daiichi Sankyo Company Ltd H2 2017
    Pipeline by Etubics Corp H2 2017
    Pipeline by F. Hoffmann-La Roche Ltd H2 2017
    Pipeline by GlaxoSmithKline Plc H2 2017
    Pipeline by Hanmi Pharmaceuticals Co Ltd H2 2017
    Pipeline by Hummingbird Bioscience Pte Ltd H2 2017
    Pipeline by ImmunoGen Inc H2 2017
    Pipeline by MediaPharma Srl H2 2017
    Pipeline by Merrimack Pharmaceuticals Inc H2 2017
    Pipeline by Merus NV H2 2017
    Pipeline by Novartis AG H2 2017
    Pipeline by Shanghai Fosun Pharmaceutical (Group) Co Ltd H2 2017
    Pipeline by Sorrento Therapeutics Inc H2 2017
    Pipeline by Symphogen A/S H2 2017
    Pipeline by Takis Srl H2 2017
    Pipeline by XuanZhu Pharma Co Ltd H2 2017
    Dormant Products H2 2017
    Dormant Products H2 2017 (Contd..1) H2 2017
    Dormant Products H2 2017 (Contd..2) H2 2017
    Discontinued Products H2 2017
    Discontinued Products H2 2017 (Contd..1) H2 2017

    List of Figures

    Number of Products under Development by Stage of Development H2 2017
    Number of Products under Development by Top 10 Indications H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    AstraZeneca Plc
    AVEO Pharmaceuticals Inc
    Celldex Therapeutics Inc
    Daiichi Sankyo Company Ltd
    Etubics Corp
    F. Hoffmann-La Roche Ltd
    GlaxoSmithKline Plc
    Hanmi Pharmaceuticals Co Ltd
    Hummingbird Bioscience Pte Ltd
    ImmunoGen Inc
    MediaPharma Srl
    Merrimack Pharmaceuticals Inc
    Merus NV
    Novartis AG
    Shanghai Fosun Pharmaceutical (Group) Co Ltd
    Sorrento Therapeutics Inc
    Symphogen A/S
    Takis Srl
    XuanZhu Pharma Co Ltd

    Request for Sample

    Report Url http://www.reportsweb.com//receptor-tyrosine-protein-kinase-erbb-3-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//receptor-tyrosine-protein-kinase-erbb-3-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//receptor-tyrosine-protein-kinase-erbb-3-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments